[膀胱非肌层浸润性移行细胞癌。诊断与治疗的新进展]

[Non-muscle invasive transitional cell carcinoma of the bladder. New developments in diagnostics and therapy].

作者信息

Sommerauer M, Jocham D, Laturnus J M

机构信息

Klinik und Poliklinik für Urologie, UK-SH Campus Lübeck, Ratzeburgerallee 160, 23568 Lübeck.

出版信息

Urologe A. 2012 Jun;51(6):791-7. doi: 10.1007/s00120-012-2897-3.

DOI:10.1007/s00120-012-2897-3

Abstract

Due to the high incidence and recurrence rate non-muscle invasive bladder cancer (NMIBC) has a relevant impact. Raman spectroscopy and optical coherence tomography represent innovative diagnostic tools. Urine markers still play a minor role in the diagnostics of NMIBC. New therapeutic options are thermochemotherapy and mitomycin-C electromotive drug administration (MMC-EMDA) as well as gemcitabine and apaziquone for intravesical administration.

摘要

由于非肌肉浸润性膀胱癌（NMIBC）的高发病率和复发率，其具有重大影响。拉曼光谱和光学相干断层扫描是创新的诊断工具。尿液标志物在NMIBC的诊断中仍起次要作用。新的治疗选择包括热化疗和丝裂霉素C电动药物给药（MMC-EMDA），以及用于膀胱内给药的吉西他滨和阿帕唑醌。

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Non-muscle invasive transitional cell carcinoma of the bladder. New developments in diagnostics and therapy].

Urologe A. 2012 Jun;51(6):791-7. doi: 10.1007/s00120-012-2897-3.

2

Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).

Pathol Res Pract. 2017 Sep;213(9):1078-1081. doi: 10.1016/j.prp.2017.07.026. Epub 2017 Aug 1.

3

[Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].

Aktuelle Urol. 2010 Sep;41(5):307-15. doi: 10.1055/s-0030-1262555. Epub 2010 Sep 7.

4

[Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy].

Prog Urol. 2016 Nov;26(14):860-864. doi: 10.1016/j.purol.2016.09.057. Epub 2016 Oct 3.

5

Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.

Eur Urol. 2016 Jun;69(6):1046-52. doi: 10.1016/j.eururo.2016.01.006. Epub 2016 Jan 20.

6

Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.

Urol Oncol. 2011 May-Jun;29(3):259-64. doi: 10.1016/j.urolonc.2009.02.012. Epub 2009 Apr 22.

7

EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.

8

Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.

World J Urol. 2009 Jun;27(3):325-30. doi: 10.1007/s00345-009-0389-x. Epub 2009 Feb 21.

9

Management of high-risk non-muscle invasive bladder cancer.

Minerva Urol Nefrol. 2012 Dec;64(4):255-60.

10

The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.

Scand J Urol. 2018 Oct-Dec;52(5-6):385-388. doi: 10.1080/21681805.2018.1548502. Epub 2019 Jan 10.

引用本文的文献

1

[Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder].

Urologe A. 2019 Jan;58(1):34-40. doi: 10.1007/s00120-018-0624-4.

2

[Urine cytology - update 2013. A systematic review of recent literature].

Urologe A. 2013 Sep;52(9):1207-24. doi: 10.1007/s00120-013-3301-7.

本文引用的文献

1

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x.

2

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

J Urol. 2011 Dec;186(6):2158-67. doi: 10.1016/j.juro.2011.07.076. Epub 2011 Oct 19.

3

Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.

Eur Urol. 2011 Sep;60(3):484-92. doi: 10.1016/j.eururo.2011.05.053. Epub 2011 Jun 12.

4

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.

Eur Urol. 2011 Jun;59(6):997-1008. doi: 10.1016/j.eururo.2011.03.017. Epub 2011 Mar 22.

5

Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis.

Int J Technol Assess Health Care. 2011 Jan;27(1):3-10. doi: 10.1017/S0266462310001364. Epub 2011 Jan 25.

6

Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).

BJU Int. 2011 Mar;107(6):912-8. doi: 10.1111/j.1464-410X.2010.09654.x. Epub 2010 Oct 4.

7

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.

Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040.

8

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.

Eur Urol. 2010 May;57(5):766-73. doi: 10.1016/j.eururo.2009.12.024. Epub 2009 Dec 18.

9

Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.

Eur Urol. 2010 Apr;57(4):595-606. doi: 10.1016/j.eururo.2009.11.041. Epub 2009 Dec 2.

10

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24.